Non-Hodgkin Lymphoma

>

Latest News

DZD8586 Produces Anti-Tumor Activity and Safety in B-Cell Lymphoma
DZD8586 Produces Anti-Tumor Activity and Safety in B-Cell Lymphoma

December 27th 2023

DZD8586 results in favorable safety with limited grade 3 or greater treatment-emergent adverse effects in those with B-cell non-Hodgkin lymphoma, according to data from 2 ongoing phase 1 trials.

Single-Agent Odronextamab Efficacy, Safety Upheld in Relapsed/Refractory DLBCL
Single-Agent Odronextamab Efficacy, Safety Upheld in Relapsed/Refractory DLBCL

December 10th 2023

Treatment with EX103 produces deep responses among heavily pretreated patients with B-cell non-Hodgkin lymphoma across multiple subgroups in a phase 1 trial.
EX103 Yields Preliminary Activity, Tolerability in R/R Non-Hodgkin Lymphoma

October 23rd 2023

Findings from a multi-center phase 1/2 trial highlight only that only grade 1 cytokine release syndrome events occurred among patients with indolent non-Hodgkin lymphoma receiving MB-106.
MB-106 Garners Responses, Favorable Safety in R/R B-Cell Non-Hodgkin Lymphoma

August 30th 2023

Findings from a retrospective analysis suggest an association between bridging therapy and poorer outcomes among patients with aggressive, relapsed/refractory B-cell non-Hodgkin lymphoma.
More Therapies Prior to CAR T May Worsen Outcomes in Non-Hodgkin Lymphoma

August 11th 2023

Video Interviews
Podcasts

More News